Skip to main
EQ

Equillium Inc (EQ) Stock Forecast & Price Target

Equillium Inc (EQ) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Equillium is a biotechnology company focused on developing novel therapies for patients with severe autoimmune and inflammatory disorders. The company's lead candidate, EQ504, is a potent and selective AhR modulator that is being developed for targeted local delivery in ulcerative colitis and other gastrointestinal diseases. Equillium's well-funded position and strong management team make it a promising investment opportunity, with potential for significant upside as the company advances its pipeline of innovative treatments.

Bears say

Equillium is a clinical-stage biotechnology company with a focus on developing novel therapies for autoimmune and inflammatory disorders. Their lead therapeutic candidate, EQ504, has shown potential in the treatment of ulcerative colitis and other gastrointestinal diseases. Despite positive pre-clinical data and a promising mechanism of action, risks related to clinical execution, financing, and competition could hinder its success. However, the recent findings highlighting EQ504's potential for deeper and more durable mucosal healing compared to competitors could increase its likelihood of success.

Equillium Inc (EQ) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Equillium Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Equillium Inc (EQ) Forecast

Analysts have given Equillium Inc (EQ) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Equillium Inc (EQ) has a Strong Buy consensus rating as of Jun 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Equillium Inc (EQ)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.